Posted by Michael Wonder on 15 Apr 2021
Orladeyo now reimbursable in Japan via National Health Insurance
15 April 2021 - Japan’s National Health Insurance System has approved the addition of Orladeyo (berotralstat), an oral preventive treatment for hereditary angioedema attacks, to its drug price list.
This means that the NHI will reimburse hospitals and pharmacies prescribing Orladeyo to a certain amount under national health insurance programs.
